Takeda Pharmaceuticals

Sarepta Therapeutics

Follow

Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We’re ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient. We’re collaborating with health networks and payers, rethinking pricing models for revolutionary new treatments in development. We are in a daily race to transform genetic understanding into genetic medicine. Because every day is an opportunity to save lives stolen by rare disease.

Lundbeck

Follow

Today, millions of people all over the world live with brain diseases. Every day, at Lundbeck we strive to further understand these diseases, develop the best therapies to treat them and make a difference to people living with them. We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization. Our purpose is clear: We are committed to advancing brain health and transforming lives Driven by research… For more than 70 years, we’ve been pushing the boundaries of neuroscience. By combining the logic of science with our passion for making a difference to patients, we’ve pioneered some of the most important and commonly used therapies within antipsychotics and antidepressants. We work closely with patients, healthcare professionals and the neuroscience community to uncover causes and to find new treatments that can bring back quality of life to people living with brain diseases. …raising our voice… When every other organ in our body gets sick, we find compassion and care. When our brain suffers, the world typically turns away. As a global specialist, we owe it to those who live with brain diseases to fight stigma and promote better treatment. That’s why we work to improve understanding and parity of care across communities and societies – so we can empower people and rebuild hope. …giving profit a purpose… The Lundbeck Foundation is the majority owner of Lundbeck. Foundation ownership allows us to stay focused on our areas of specialization. It also means that we are in a position to give back. With donations of approximately DKK 500 million a year to biomedical research, the foundation supports the progress of health science. …and working with one aim. Today, we’re over 5,000 people in +20 countries. We build on our Danish heritage, fostering a culture of collaboration and responsibility. Whether we work in labs or in the field, we all have the same aim: to develop innovative treatments that improve the lives of people living with brain diseases.

Ultragenyx

Follow

At Ultragenyx, we’re going beyond every day to transform the lives of people living with rare diseases and lead the future of rare disease medicine. We built our team and our company from the ground up to pioneer new medicines and approaches to drug development for rare and ultrarare diseases and overcome the challenges inherent to treating small patient populations and previously untreated conditions. In 15 years, we’ve achieved four approved therapies in five indications, with a robust pipeline of late-stage therapeutic candidates for debilitating conditions. Our approach to development is informed by patient experience and insights, and we share our science and expertise to help move the entire field forward.

Biogen

Follow

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

GSK

Follow

GSK is a global biopharma company with a special purpose – to unite science, technology and talent to get ahead of disease together – so we can positively impact the health of billions of people and deliver stronger, more sustainable shareholder returns – as an organisation where people can thrive. Getting ahead means preventing disease as well as treating it, and we aim to impact the health of 2.5 billion people around the world in the next 10 years. NOTICE: Salary ranges on this site are estimates provided by Glassdoor and have not been verified by GSK. GSK Recruiters will share the salary range during the Recruitment process.

Daiichi Sankyo

Follow

Daiichi Sankyo, Inc. is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, pain management, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma.